Discover the people behind the brand and how we got started.
About Us
Noxsano™ is a wound care company dedicated to developing medical treatments for the human and veterinary doctor that deliver biosignaling molecules to enable effective treatment of acute and chronic wounds. Noxsano’s patented technology has been shown in pre-clinical and clinical testing to restore normal wound healing to ischemic (chronic) wounds and to accelerate the healing of acute and burn wounds.
Noxsano was founded by a team of innovative scientists and healthcare professionals with experience at Procter & Gamble, McKesson, and several other large healthcare companies. They are supported by a world-class team of advisors with experience ranging from wound care clinicians to senior J&J executives.
Learn more about the Noxsano origin story in The Collaborative Vet video podcast interview with one of our founders, or scroll down to meet the rest of the team.
The Noxsano Origin Story
Meet the Team
Alan Willey PhD
A proven innovator, Alan spent 26 years at P&G leading an upstream R&D group focused on the development of energy-activated chemical technologies. He holds more than 100 patents.
CEO
Jacob Adams PhD
Jacob spent thirteen years as a scientist at P&G developing activated technologies providing point-of-use benefits to consumers. He holds 20 granted or pending patents.
CSO
Stevan Samuel PhD
COO
Stevan has more than a decade of experience in product development, including product development at P&G and utilizing open innovation and lean startup principles to help Fortune 500 companies build scaleable businesses.
Ray Shealy
Ray is a successful operator, investor, and board member of a number of healthcare and technology-based companies. He is adept at helping companies grow exponentially by focusing on strategy, innovation, and execution.
Cofounder
Randy Watson PhD
Randy has 30 years of international R&D management experience at P&G with extensive go-to-market and new business development experience. He holds more than 20 granted US patents.
Marketing Director
Our Advisors
Shu is the CEO of the US Institute for Advanced Sinus Care and Research, the CMO for Tivic Health, Inc. and the former Director of Sinus Surgery at The Ohio State University. Shu has extensive experience in the wound healing space. His NIH-funded research on biofilms won the 2013 Edmund Prince Fowler Award, the top basic science research award in the field of otolaryngology-head and neck surgery. He served as a consultant for Medtronic ENT where he worked on the development of a chitosan-based dressing for improved wound healing after sinus surgery. At Tivic Health, Shu was key to the creation of an electroceutical device for sinus headaches that won the Time Magazine 2019 Invention of the Year for Healthcare. Recognized as one of the nation's best sinus surgeons, Shu is also a Fellow of the American Rhinologic Society, where he received a Presidential Citation in 2015.
Subinoy Das MD FACS
Arti is a board-certified MD (internal medicine) with 15+ years in medical leadership, including 2+ years as CMO and 3 years in clinical and wound care innovation. She possesses deep knowledge of healthcare operations and currently serves as an Executive at Humana in their Executive in Rotation Program. Previously she served as CMO at Misonix, (NASDAQ: MSON), following their Sept 2019 acquisition of Solsys. Prior to that, Arti was the Executive Vice President of Clinical Innovation at Healogics, a PE-owned operator of 650+ outpatient wound care centers. Healogics acquired Accelecare Wound Centers, private equity-backed business and Wound Specialists of Greater Cincinnati PLLC, which Arti founded in 2009 and served as CEO, establishing a first-of-its-kind value-based clinical care model and network of hospital treatment centers.
Arti Masturzo MD MBA
Vance has over 25 years of experience in the medical device space and currently is CEO of Lineus Medical, a company launching the first patient safety disconnect for protecting peripheral IV lines. Previously, Vance served in various sales and marketing roles with both start-up and mature companies, including Vice President of Sales and Marketing at BlueInGreen, a start-up that develops and manufactures capital equipment dissolving gases into liquids for water treatment. Vance was Sr. Director of Marketing at Mako Surgical, which introduced the first successful robotic guided surgery into orthopaedic joint replacement. Vance spent 16 years working for Smith & Nephew Orthopaedics and Wright Medical in various manufacturing, and senior marketing and sales roles. Vance has led teams in product development, medical education, regulatory approval and marketing for over 20 different medical devices.
Vance Clement BSIE MBA
Larry serves as an Operating Advisor for Avista Capital where he previously served as the Chairman of Global Healthcare for 10 years. Prior to that he spent 32 years with Johnson & Johnson where he had various roles including Chairman of J&J Development (a global corporate venture capital operation with investments in over 150 startups), President of Ortho Dermatology, President of Janssen Pharmaceuticals, Chairman of Janssen Americas and Chairman Worldwide OTC. Larry also served as Chairman of Optinose (NASDAQ: OPTN) from its inception through approval of two products and their eventual IPO. He also served as Chairman of Lantheus Holdings, and on the Board of Naviyst Medical, Bioreliance Holdings, Accellent Inc. Bio Gmbh and Point Therapeutics (dba Dara Biosciences Inc.)
Larry G. Pickering